2013 ACC/AHA cholesterol treatment guideline

What was done well and what could be done better

Research output: Contribution to journalArticle

Abstract

Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults was released. The American College of Cardiology and American Heart Association issued the guideline on the basis of a systematic review of cholesterol treatment trials performed by the National Heart, Lung, and Blood Institute. This report critically appraises the guideline and provides our view of what was done well and what could be done better. In particular, we propose that the guideline succeeds in prioritizing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke), and emphasizing absolute cardiovascular risk to determine eligibility for statin therapy. We contend that the guideline could be enhanced by refining the use of lipid goals rather than removing them, enhancing guidance on evaluation of cholesterol, and broadening the concept of age underpinning risk-based decision making to include vascular and physiological age. We further suggest that the next guideline panel could comprehensively review current best evidence, build on existing guidelines, and cultivate broader national and international consensus. Overall, we aim to continue discussions about the important contributions and shortfalls of the guideline and create momentum for effective implementation and timely updates.

Original languageEnglish (US)
Pages (from-to)2674-2678
Number of pages5
JournalJournal of the American College of Cardiology
Volume63
Issue number24
DOIs
StatePublished - Jun 24 2014

Fingerprint

Cholesterol
Guidelines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
National Heart, Lung, and Blood Institute (U.S.)
Blood Vessels
Consensus
Decision Making
Cardiovascular Diseases
Stroke
Lipids
Therapeutics

Keywords

  • atherosclerosis
  • cardiovascular disease
  • cholesterol
  • coronary heart disease
  • dyslipidemia
  • guidelines
  • lipids
  • lipoproteins
  • myocardial infarction
  • statins
  • stroke
  • treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{738f1cf66ddf48f98519ebdf67fc85d9,
title = "2013 ACC/AHA cholesterol treatment guideline: What was done well and what could be done better",
abstract = "Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults was released. The American College of Cardiology and American Heart Association issued the guideline on the basis of a systematic review of cholesterol treatment trials performed by the National Heart, Lung, and Blood Institute. This report critically appraises the guideline and provides our view of what was done well and what could be done better. In particular, we propose that the guideline succeeds in prioritizing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke), and emphasizing absolute cardiovascular risk to determine eligibility for statin therapy. We contend that the guideline could be enhanced by refining the use of lipid goals rather than removing them, enhancing guidance on evaluation of cholesterol, and broadening the concept of age underpinning risk-based decision making to include vascular and physiological age. We further suggest that the next guideline panel could comprehensively review current best evidence, build on existing guidelines, and cultivate broader national and international consensus. Overall, we aim to continue discussions about the important contributions and shortfalls of the guideline and create momentum for effective implementation and timely updates.",
keywords = "atherosclerosis, cardiovascular disease, cholesterol, coronary heart disease, dyslipidemia, guidelines, lipids, lipoproteins, myocardial infarction, statins, stroke, treatment",
author = "Seth Martin and Abd, {Thura T.} and Steven Jones and Michos, {Erin Donnelly} and Blumenthal, {Roger S} and Michael Blaha",
year = "2014",
month = "6",
day = "24",
doi = "10.1016/j.jacc.2014.02.578",
language = "English (US)",
volume = "63",
pages = "2674--2678",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "24",

}

TY - JOUR

T1 - 2013 ACC/AHA cholesterol treatment guideline

T2 - What was done well and what could be done better

AU - Martin, Seth

AU - Abd, Thura T.

AU - Jones, Steven

AU - Michos, Erin Donnelly

AU - Blumenthal, Roger S

AU - Blaha, Michael

PY - 2014/6/24

Y1 - 2014/6/24

N2 - Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults was released. The American College of Cardiology and American Heart Association issued the guideline on the basis of a systematic review of cholesterol treatment trials performed by the National Heart, Lung, and Blood Institute. This report critically appraises the guideline and provides our view of what was done well and what could be done better. In particular, we propose that the guideline succeeds in prioritizing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke), and emphasizing absolute cardiovascular risk to determine eligibility for statin therapy. We contend that the guideline could be enhanced by refining the use of lipid goals rather than removing them, enhancing guidance on evaluation of cholesterol, and broadening the concept of age underpinning risk-based decision making to include vascular and physiological age. We further suggest that the next guideline panel could comprehensively review current best evidence, build on existing guidelines, and cultivate broader national and international consensus. Overall, we aim to continue discussions about the important contributions and shortfalls of the guideline and create momentum for effective implementation and timely updates.

AB - Five years after convening the expert panel, the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults was released. The American College of Cardiology and American Heart Association issued the guideline on the basis of a systematic review of cholesterol treatment trials performed by the National Heart, Lung, and Blood Institute. This report critically appraises the guideline and provides our view of what was done well and what could be done better. In particular, we propose that the guideline succeeds in prioritizing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke), and emphasizing absolute cardiovascular risk to determine eligibility for statin therapy. We contend that the guideline could be enhanced by refining the use of lipid goals rather than removing them, enhancing guidance on evaluation of cholesterol, and broadening the concept of age underpinning risk-based decision making to include vascular and physiological age. We further suggest that the next guideline panel could comprehensively review current best evidence, build on existing guidelines, and cultivate broader national and international consensus. Overall, we aim to continue discussions about the important contributions and shortfalls of the guideline and create momentum for effective implementation and timely updates.

KW - atherosclerosis

KW - cardiovascular disease

KW - cholesterol

KW - coronary heart disease

KW - dyslipidemia

KW - guidelines

KW - lipids

KW - lipoproteins

KW - myocardial infarction

KW - statins

KW - stroke

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84902603181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902603181&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.02.578

DO - 10.1016/j.jacc.2014.02.578

M3 - Article

VL - 63

SP - 2674

EP - 2678

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 24

ER -